Ambrosia Bio

Ambrosia Bio is dedicated to forging a healthier world through its innovative enzyme technology platform, which is designed to convert obesity-promoting industrial sugars into minimal-calorie rare sugars. The company's B2B business model offers leading sugar and juice manufacturers the ability to reduce sugar content without compromising taste. With a foundation in biotechnology, food and beverage, and nutrition, Ambrosia Bio, founded in 2020 and headquartered in Israel, is well-positioned to address the rising demand for Allulose. However, as there is no information available about the last investment or investors, it remains to be seen how this promising startup will continue to attract funding and develop its disruptive technology.